Human Amniotic Epithelial Cell Transplantation Induces Markers of Alternative Macrophage Activation and Reduces Established Hepatic Fibrosis by Manuelpillai, Ursula et al.
Human Amniotic Epithelial Cell Transplantation Induces
Markers of Alternative Macrophage Activation and
Reduces Established Hepatic Fibrosis
Ursula Manuelpillai
1, Dinushka Lourensz
2,5, Vijesh Vaghjiani
1, Jorge Tchongue
2,5, Derek Lacey
3, Jing-
Yang Tee
1, Padma Murthi
4,6, James Chan
2, Alexander Hodge
2,5, William Sievert
2,5*
1Center for Reproduction and Development, Monash Institute of Medical Research, Monash University, Melbourne, Australia, 2Center for Inflammatory Diseases, Monash
University, Melbourne, Australia, 3University of Melbourne, Arthritis and Inflammation Research Centre, Royal Melbourne Hospital, Melbourne, Australia, 4Department of
Obstetrics and Gynecology, University of Melbourne, Melbourne, Australia, 5Gastroenterology and Hepatology Unit, Southern Health, Melbourne, Australia, 6
Research Center, Royal Women’s Hospital, Melbourne, Australia
Abstract
Chronic hepatic inflammation from multiple etiologies leads to a fibrogenic response that can progress to cirrhosis and liver
failure. Transplantation of human amniotic epithelial cells (hAEC) from term delivered placenta has been shown to decrease
mild to moderate hepatic fibrosis in a murine model. To model advanced human liver disease and assess the efficacy of
hAEC therapy, we transplanted hAEC in mice with advanced hepatic fibrosis. Immunocompetent C57BL/6 mice were
administered carbon tetrachloride (CCl4) twice weekly resulting in bridging fibrosis by 12 weeks. hAEC (2610
6) were infused
via the tail vein at week 8 or weeks 8 and 10 (single and double dose, respectively). Human cells were detected in mouse
liver four weeks after transplantation showing hAEC engraftment. CCl4 treated mice receiving single or double hAEC doses
showed a significant but similar decrease in liver fibrosis area associated with decreased activation of collagen-producing
hepatic stellate cells and decreased hepatic protein levels of the pro-fibrogenic cytokine, transforming growth factor-beta1.
CCl4 administration caused hepatic T cell infiltration that decreased significantly following hAEC transplantation. Hepatic
macrophages play a crucial role in both fibrogenesis and fibrosis resolution. Mice exposed to CCl4 demonstrated increased
numbers of hepatic macrophages compared to normal mice; the number of macrophages decreased significantly in CCl4
treated mice given hAEC. These mice had significantly lower hepatic protein levels of the chemokine monocyte
chemoattractant protein-1 than mice given CCl4 alone. Alternatively activated M2 macrophages are associated with fibrosis
resolution. CCl4 treated mice given hAEC showed increased expression of genes associated with M2 macrophages including
YM-1, IL-10 and CD206. We provide novel data showing that hAEC transplantation induces a wound healing M2
macrophage phenotype associated with reduction of established hepatic fibrosis that justifies further investigation of this
potential cell-based therapy for advanced hepatic fibrosis.
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Introduction
Chronic hepatic inflammation from diverse causes including
alcohol, steatohepatitis, autoimmune disease and viral infection
leads to a wound healing, pro-fibrogenic response. In some
patients with ongoing liver injury, this response can progress to
cirrhosis, portal hypertension and liver failure [1]. These
outcomes are associated with a significant mortality rate for
which liver transplantation is the only curative therapy [2,3].
However, low donor numbers, high procedural costs and the
requirement for life-long immunosuppression limit the number of
patients who undergo transplantation and consequently alterna-
tive therapies have been sought. Among these, the trans-
plantation of hematopoietic and mesenchymal stem cells derived
from adult bone marrow and placenta have shown beneficial
effects in animal models of hepatic fibrosis [4,5,6,7] leading to
early phase clinical trials using autologous bone marrow derived
cells [8,9,10,11]. Most of the clinical trials have been small, often
with less than ten patients, and uncontrolled but have shown
short-term clinical benefits [12]. Recently, we have shown that
transplantation of placenta derived human amniotic epithelial
cells (hAEC) into immunocompetent mice with carbon tetra-
chloride (CCl4) induced liver fibrosis can constrain hepatic
fibrogenesis [13]. This outcome may be related to several factors
linked to hAEC transplantation including reduction in the
expression of pro-inflammatory and pro-fibrogenic cytokines
coupled with the induction of matrix metalloproteinases to
promote a collagen-degrading environment [13].
During pregnancy, hAEC form a monolayer lining the inner
of two membranes retaining the amniotic fluid surrounding the
fetus. Unlike adult bone marrow derived stem cells, hAEC are
highly abundant and easily harvested from term delivered
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Pregnancy
  Department  of  Perinatal  Medicine, amnion membranes typically yielding over 150610
6 cells/
membrane and thereby minimizing the need for expensive
and time consuming cell expansion [14]. hAEC are derived
from embryonic epiblast cells prior to gastrulation and possess
some features of their founder pluripotent stem cells including
the ability to differentiate into multiple lineages derived from
the primary germ layers [14,15]. Importantly, like other fetal-
derived placental cells that evade maternal immune recognition
and secrete factors known to dampen maternal immune
responses against the fetal semi-allograft, hAEC have also been
shown to have low immunogenicity and the capacity to
modulate innate and adaptive immune cell responses
[14,16,17]. Collectively, these features make hAEC an attractive
source of cells for potential therapeutic applications.
While we have shown ameliorative effects of hAEC trans-
plantation on hepatic fibrosis, our study and others investigating
stem cells were carried out predominantly in models of acute or
short-term inflammation in which primarily mild fibrosis was
evident [5,6,13]. Therefore, the effects of cellular therapy in
models of chronic inflammation with well established fibrosis,
which better reflect the clinical problem of advanced liver disease
and cirrhosis, remain uncertain. Furthermore, there is no data on
the efficacy of an additional cell dose or the generation of
antibodies against the transplanted cells which may influence the
timing and donor selection for subsequent treatments. Thus, using
mice chronically injured with long-term CCl4 treatment, we
investigated the efficacy of a single versus double hAEC dose and
the effect of transplanted hAEC on host T cells and anti-hAEC
antibody generation. In order to gain an understanding of
potential anti-fibrotic mechanisms, we studied the effects of hAEC
transplantation on hepatic macrophages that play a pivotal role in
mediating fibrogenesis and fibrosis resolution [18,19].
Materials and Methods
Ethics Statement
The study was approved by the Southern Health and Royal
Women’s Hospital Human Research Ethics Committees and
Monash University and University of Melbourne Institutional
Review Boards. Informed, written consent was obtained from
healthy women with a normal singleton pregnancy prior to
elective cesarean section at term (37–40 weeks gestation; n=16).
Six week old male C57BL/6 mice were purchased from Monash
Animal Services, Melbourne, Australia. Experimentation on
C57BL/6 mice was approved by the Animal Ethics Committee,
Monash University (approval number MMCB 2008/17).
Isolation of hAEC
hAEC were isolated from amnion membranes and purity
assessed as described previously [20]. Briefly, amnion membranes
were cut into small pieces and digested twice in 0.05%
trypsin:EDTA (Gibco, Grand Island, NY) for 40 min at 37uC.
Following inactivation of trypsin with newborn calf serum,
dispersed cells were washed in DMEM/F12 medium (Gibco)
and erythrocytes lysed in hypotonic solution. Batches $99%
positive for the epithelial markers cytokeratin-7 and 8/18 (Dako,
Glostrup, Denmark) by flow cytometry and displaying a cobble-
stone epithelial morphology in culture [21], were transplanted into
C57BL/6 mice (Figure S1).
hAEC-splenocyte Co-culture
hAEC have been shown to suppress T cell proliferation in
hAEC-splenocyte co-culture assays [17,22]. To explore whether
apoptosis played a role, hAEC were co-cultured with murine
splenocytes stimulated with the mitogen Concanavalin A. The
CD45+/CD3+/Annexin V+ cell population was determined by
flow cytometry. Primary antibodies were linked to PE, Cy7 and
FITC (BD Biosciences) and diluted 1:200, 1:50 and 1:20,
respectively.
Murine Hepatic Stellate Cell (HSC) Isolation and
Atreatment
HSC were isolated as described previously [23]. Briefly livers
were perfused and digested with collagenase and pronase. HSC
were isolated by Nycodenz density gradient centrifugation and
purity was determined by vitamin A autofluorescence. To examine
the effects of factors secreted by hAEC on transforming growth
factor beta-1 (TGFb-1) and collagen, murine HSC were grown in
24 well plates and stimulated with 25% hAEC conditioned media
for 48 h. TGFb-1 was measured by ELISA and collagen synthesis
by the
3H-proline incorporation assay. HSC were washed,
incubated on ice with trichloroacetic acid and sodium hydroxide
added. Equal volumes of lysate and hydrochloric acid were added
to 10 parts scintillation fluid and the beta emission was measured.
Induction of Hepatic Fibrosis and hAEC Transplantation
Intraperitoneal injections of CCl4 (Merck, Darmstadt, Ger-
many; 1 ml/g body weight diluted 1:10 in olive oil) were
administered to mice twice weekly for 12 weeks. hAEC (2610
6)
were injected via the tail vein at week 8 (single dose group) or at
weeks 8 and 10 (double dose group) of CCl4 treatment. The
number of hAEC infused was based on previous experiments to
identify the optimal dose [13]. Control groups consisted of mice
given CCl4 only and healthy, untreated mice. Each cohort
consisted of n=8 mice. The animals were culled at 12 weeks and
blood and liver tissue collected.
Detection of Anti-hAEC Antibodies in Murine Serum
hAEC (2610
6; n=4) were injected into healthy C57BL/6 mice
(n=4) and blood collected two weeks later (single cell dose group).
Cell injection was repeated immediately after the first blood
collection and blood collected again after a further two weeks
(double cell dose group). To determine if there were anti-hAEC
antibodies, the murine serum was diluted 1:100 and mixed with
suspensions of the same batches of hAEC that had been injected
previously. The hAEC and serum were incubated for 30 min to
enable anti-hAEC antibodies present in the murine serum to bind
to the cells. Following three washes, the hAEC were incubated for
30 min with rabbit anti-mouse AlexaFluro-488 secondary anti-
body (1:100; Molecular Probes, Eugene, OR). Cells were washed
thoroughly and analysed by flow cytometry. hAEC alone and cells
incubated with serum from healthy, non-injected mice served as
negative controls.
Immunohistochemistry
Mouse liver tissue was fixed in 10% neutral buffered
formalin. Paraffin sections, 4 mm in thickness were dewaxed
and rehydrated. hAEC present in the liver were identified by
detecting human inner mitochondrial membrane (IMM; 1:100;
Millipore, Billerica, MA) protein and human leukocyte antigen
(HLA)-G (1:50; BD Biosciences, San Jose, CA) on serial sections
following antigen retrieval in 0.01 M citrate buffer [13]. To
examine if hAEC in the liver displayed features of mature
hepatocytes, serial sections were stained for human albumin
(1:5000; Abcam, Cambridge, UK) and hepatic nuclear factor 4
alpha (HNF4a; 1:150; Cell Signalling Technology, Danvers,
MA) after antigen retrieval in citrate buffer. Hepatic macropha-
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Dr Richard Kitching, Monash University); T cells with
biotinylated CD3 (1:200; BD Biosciences), CD4 and CD8
(1:100 and 1:50, respectively; from Dr R Kitching) and
activated HSC or myofibroblasts using a-smooth muscle actin
(a-SMA; 1:5000; Sigma-Aldrich, St Louis, MO).
Briefly, endogenous peroxidase activity was quenched by adding
0.3–3% H2O2 (IMM, HLA-G, F4/80, albumin, CD4, CD8,
HNF4a) or peroxidase block (Dako; a-SMA, CD3). Non-specific
binding was minimized with CAS protein blocking solution
(Invitrogen, Camarillo, CA). Primary antibodies were incubated
at room temperature for 30 min (a-SMA) or overnight at 4uC.
Primary antibodies were either omitted from negative controls
(F4/80, albumin, HNF4a) or incubated with isotype matched IgG
(a-SMA) or pre-immune serum (IMM, HLA-G, CD3, CD4,
CD8). After several washes sections were incubated with
biotinylated rabbit anti-mouse IgG2a (Invitrogen; 1:300; a-SMA,
IMM, HLA-G, CD3), goat anti-rabbit IgG (Vector Laboratories,
Burlingame, CA; 1:200; albumin, HNF4a) or rabbit anti-rat IgG
(Dako; 1:150; F4/80, CD4, CD8). Antibody binding was detected
using ABC kit reagents (Vector Laboratories) followed by DAB
chromogen (Sigma-Aldrich). Slides were lightly counterstained
with hematoxylin and mounted in DPX.
Picrosirius Red Staining and Computer-assisted
Morphometry
To identify the extent of histological fibrosis, 4 mm thick
deparaffinized liver sections were stained as previously described
[13]. Briefly, sections were incubated in picrosirius red (Sigma-
Aldrich; Direct Red 80, 0.1% wt/vol in saturated picric acid) for
90 min and washed with acetic acid and water (1:200). Fifteen
non-overlapping fields were acquired, images digitized and fibrosis
area measured by computer-assisted morphometry using Scion
Image for Windows (vAlpha 4.0.3.2, Scion Corporation, Freder-
ick, MD).
Enzyme-linked Immunosorbent Assays (ELISA)
The concentrations of TGFb-1, fractalkine (CX3CL1) and
monocyte chemoattractant protein-1 (MCP-1) in liver tissue were
measured by ELISA. Snap frozen liver tissue (,150 mg) was
homogenized in lysis buffer (50 mM Tris-HCl, 150 mM NaCl,
1 mM EDTA, 1% Triton X-100, 0.5% Tween-20, 0.1% SDS)
containing a protease inhibitor cocktail (Roche, Mannheim,
Germany). Lysates were sonicated and centrifuged at 14,000 g
for 15 min at 4uC and supernatants collected. For TGFb-1
measurement samples were activated with acetic acid/urea.
ELISA plates were coated with antibodies against murine
TGFb-1 and CX3CL1 (R&D Systems, Minneapolis, MN) and
murine MCP-1 (BD Pharmingen, San Diego, CA). Tissue lysates
or media from murine HSC cultures were added and plates
incubated for 2 h at room temperature. After several washes
detection reagents were added and absorbencies read on
a microplate reader (Magellan, Tecan, Austria). The concentra-
tions were calculated from the standard curve generated by the
plate reader software. The data was normalized against total
protein concentrations that were measured using the BCA assay
(Thermo Scientific, Rockford, IL).
Real Time Quantitative Polymerase Chain Reaction (RT-
qPCR)
The expression of M1 and M2 associated macrophage genes
and matrix metalloproteinase (MMP) genes was studied by RT-
qPCR. Total RNA was isolated from snap frozen liver tissue using
the RNeasy mini kit (Qiagen, Hilden, Germany). RNA was
converted to cDNA using the High-Capacity Reverse Transcrip-
tion Kit (Applied Biosystems, Foster City, CA) and amplified using
Power Sybr Green (Applied Biosystems, Warrington, UK) on
a Rotor Gene 3000 light cycler (Qiagen, Sydney, Australia). The
nucleotide sequences of primers used in the PCR are listed in
Table 1. Samples were denatured at 95uC for 15 sec and
annealed/extended at 60uC for 1 min for 40 cycles. Data was
normalized to GAPDH and fold change calculated by the
DDCT
method using healthy mice as the calibrator.
Statistical Analysis
Data were analysed by one-way ANOVA with Tukey’s post hoc
test for multiple comparisons. Planned comparisons of numbers of
hAEC engrafted in the liver following a single and double dose
were analysed by Student’s t test. Analyses were carried out using
GraphPad Prism software (v5.0d for Mac OS X, San Diego, CA).
P,0.05 was considered to be statistically significant. Data are
shown as mean6SEM.
Results
Histological Liver Fibrosis Increases Over Time Following
CCl4 Administration
The extent of histological fibrosis was determined in picrosirius
red-stained liver tissue sections. Twice weekly intraperitoneal
administration of CCl4 to wild type C57BL/6 mice over a period
of 4–12 weeks resulted in a progressive increase in histological
fibrosis. Minimal fibrosis was seen at 4 weeks while there was clear
evidence of bridging fibrosis at 12 weeks (Figure S2A). Fibrosis
area, determined by computer-assisted morphometry, increased
by nearly 50% from 4 to 8 weeks of CCl4 treatment (mean values
of 2.07% and 3.01% at 4 and 8 weeks, respectively) and to 3.9 and
4.25% fibrosis area by weeks 10 and 12, respectively (P,0.05 vs 4
weeks; Figure S2B). Based on these findings, hAEC were
transplanted at week 8 of CCl4 administration to test the anti-
fibrotic efficacy of a single dose. To test the effect of a second dose
in advanced fibrosis, hAEC were injected into a separate group of
mice at week 8 and again at week 10. CCl4 administration
continued until week 12, when both treated and control animals
were culled.
hAEC Engraft in Mouse Liver and Decrease CCl4-induced
T Cell Infiltration
Intravenously infused hAEC were detected in liver tissue by
immunohistochemistry for IMM protein and HLA-G. Intact,
positively stained cells for both human markers were identified in
serial tissue sections of animals given single and double hAEC
doses (Figure 1A). hAEC were scattered throughout the hepatic
acinus but were found predominantly in zone 1. These findings
confirm that the infused hAEC had migrated, engrafted and
remained in the injured liver for 2 to 4 weeks following cell
transplantation. The number of IMM and HLA-G positive cells
present in the liver increased with the second injection (mean 6
SEM/high power microscopic field =3.0360.41 and 4.8360.52
for single and double doses, respectively; P,0.05). Infused hAEC
express several hepatocyte specific genes including albumin but
lack HNF4a, a key transcription factor present in mature
hepatocytes [24]. Engrafted hAEC (HLA-G+ cells) were albumin
positive and some were HNF4a+ (Figure S3), suggesting that some
of the engrafted hAEC had differentiated into mature hepatocyte-
like cells in the liver.
Given the presence of hAEC in mouse liver, we next
determined whether there was an effect on T cells that could
Placental Amnion Cells Reduce Liver Fibrosis
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of the engrafted hAEC. We found an increase in hepatic CD3
positive T cells with CCl4 treatment, consistent with reports of
elevated T cell numbers in liver inflammation and fibrosis [25],
(Figure 1B). Interestingly, subsequent to the single and double
hAEC doses, the number of CD3 positive cells was reduced
(P,0.05 and 0.01 for CCl4 vs single and double doses,
respectively). Dense cellular infiltration typically seen in cell-
mediated graft rejection was not observed in the liver sections.
Analysis of T cell sub-populations showed that the number of
CD4+ cells remained unaltered whereas CD8+ cells were lower in
hAEC treated mice (P,0.05 for CCl4 vs single dose; Figure 1B
and Figure S4). We explored if hAEC induced apoptosis
contributed to the overall reduction in T cell numbers. However,
the CD45+/CD3+/annexin V+ population remained unaltered
when murine splenocytes were co-cultured with hAEC (data not
shown).
Transplanted hAEC Elicit an Antibody Response
In separate experiments, we examined whether a humoral
response with murine anti-hAEC antibodies was generated against
the transplanted cells by analysing sera collected two weeks after
healthy mice were given single and double hAEC doses. Similar
levels of anti-hAEC antibodies were present in mice given single
and double cell doses as shown by the mean fluorescence
intensities of antibody bound hAEC analysed by flow cytometry
(172.6651.1 and 226.8646 for single and double doses, re-
spectively; P=0.46, Figure 1C), indicating that a second hAEC
infusion did not lead to further increases in circulating anti-hAEC
antibodies.
hAEC Transplantation Reduces Established Hepatic
Fibrosis in CCl4 Treated Mice
Given the evidence of a humoral immune response against
hAEC, we then examined whether the cells would be effective
in reducing established hepatic fibrosis. Computer-assisted
morphometry of picrosirius red-stained liver sections showed
significantly less fibrosis area in CCl4-treated mice given hAEC
compared to mice given CCl4 alone (P,0.05; Figure 2A). There
was no further reduction in animals receiving a second hAEC
dose. HSC are the principal collagen producing cell in the liver
and when activated to a myofibroblast phenotype show
increased expression of a-SMA. Mice given CCl4 plus hAEC
showed fewer activated HSC compared to those given CCl4
alone (P,0.01; Figure 2B) with further reduction seen in mice
receiving the double hAEC dose (P,0.001 compared to mice
given CCl4 only). TGFb-1 drives HSC activation and is thought
to be the most potent pro-fibrogenic cytokine in the liver [26].
We measured TGFb-1 protein in liver tissue lysates and found
that mice given CCl4 plus hAEC had significantly less TGFb-1
compared to mice given CCl4 alone (P,0.01; Figure 2C).
TGFb-1 levels declined further in mice treated with a double
hAEC dose (P,0.001 compared to mice given CCl4 alone). We
then explored if hAEC secreted factors acting directly on HSC
could contribute to the reduction in hepatic fibrosis and TGFb-
1. Murine HSC were stimulated with media conditioned by
hAEC. TGFb-1 output and collagen synthesis declined signif-
icantly in the treated cultures (P=0.016 and 0.003, respectively;
Figure 2D).
hAEC Transplantation Reduces Hepatic Macrophage
Numbers and Induces an M2 Phenotype
Macrophages play a pivotal role in hepatic fibrogenesis as well
as fibrosis resolution depending on their phenotype and local
environment [27,28]. Previous studies have reported a large influx
of bone marrow derived F4/80 positive monocytes in response to
elevated levels of hepatic chemokines such as MCP-1 and
fractalkine following injection of toxins such as CCl4 [25,29,30].
Consistent with these studies, the number of F4/80 positive
macrophages was elevated in CCl4 treated animals compared to
healthy mice (P,0.001; Figure 3A). However, the number of F4/
80 positive cells was significantly lower in mice treated with hAEC
Table 1. Primers used to analyze expression of M1 and M2 macrophage genes and MMP.
Gene Forward 59R39 Reverse 59R39
M1
CCL17 CGAGAGTGCTGCCTGGATTACT GGTCTGCACAGATGAGCTTGCC
CCL5 CCTGCTGCTTTGCCTACCTCTC ACACACTTGGCGGTTCCTTCGA
IL-12b CTCAGAAGCTAACCATCTCCTGG CACAGGTGAGGTTCACTGTTTC
M2
Cnrip-1 CGGCATCTATGACACAGAAGGTG GGCAATGGTCTCGCTTGTGGTA
CD206 GTTCACCTGGAGTGATGGTTCTC AGGACATGCCAGGGTCACCTTT
IL-10 CGGGAAGACAATAACTGCACCC CGGTTAGCAGTATGTTGTCCAGC
YM-1 CCAGCATATGGGCATACCTT AGACCTCAGTGGCTCCTTCA
Arg-1 CATTGGCTTGCGAGACGTAGAC GCTGAAGGTCTCTTCCATCACC
Cadm-1 ACTTCTGCCAGCTCTACACGGA CCCTTCAACTGCCGTGTCTTTC
CD36 GGACATTGAGATTCTTTTCCTCTG GCAAAGGCATTGGCTGGAAGAAC
MMP
MMP-9 CTGGACAGCCAGACACTAAAG CTCGCGGCAAGTCTTCAGAG
MMP-12 CATGAAGCGTGAGGATGTAGAC TGGGCTAGTGTACCACCTTTG
Housekeeping
GAPDH TGTTCCTACCCCCAATGTGT TGTGAGGGAGATGCTCAGTG
doi:10.1371/journal.pone.0038631.t001
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explore potential mechanisms that could lead to a reduction in
macrophage numbers, we measured MCP-1 protein in mouse liver
tissue lysates and found less MCP-1 in mice treated with hAEC
(P,0.05 vs. CCl4 treated animals; Figure 3B). In contrast, hepatic
fractalkine protein levels increased in mice treated with hAEC
(P,0.01 and 0.001 for single and double hAEC doses, re-
spectively).
The polarization of macrophages to a M2 alternatively
activated phenotype is associated with hepatic wound healing
[30]. We therefore examined the phenotype of the hepatic
macrophage population by determining gene expression of known
macrophage associated markers in whole liver extracts. We found
that CCl4-treated mice which had been infused with hAEC had
increased mRNA expression of M2 associated markers YM-1
(P,0.05), CD206 and IL-10 (P,0.01; Figure 4A) compared with
mice given CCl4 alone. Cnrip-1 expression also increased in
hAEC treated mice but did not reach significance while Arg-1 and
Cadm-1 mRNA expression remained unaltered. We also exam-
ined the expression of classically activated M1 macrophages that
have been linked to fibrosis progression [30]. We found no change
in the expression of M1 associated markers CCL17 and CCL5 in
hAEC treated mice compared with mice given CCl4 alone
(Figure 4B). We also examined the ratio of IL-12b mRNA, which
Figure 1. Engraftment of human amniotic epithelial cells (hAEC) in the liver and immune surveillance. A single or double hAEC dose
was infused intravenously into C57BL/6 mice with established fibrosis induced by prolonged carbon tetrachloride (CCl4) treatment. Engrafted hAEC
were identified by immunohistochemistry for human inner mitochondrial membrane (IMM) protein and HLA-G on serial tissue sections (A). The
numbers of CD3 and CD8 positive T cells in the liver were significantly lower in mice treated with hAEC (B). Serum from mice injected with hAEC
contained anti-hAEC antibodies that bound to hAEC and were detected by flow cytometry. Red and blue lines on the representative flow plot shown
correspond to single and double hAEC infusions, respectively. Controls (grey lines) consisted of hAEC alone or hAEC reacted with serum from non-
injected mice (C). Scale bar =50 mm (IMM/HLA-G). *, ** and *** = P,0.05, 0.01 and 0.001, respectively.
doi:10.1371/journal.pone.0038631.g001
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actin (a-SMA) immunohistochemistry of activated hepatic stellate cells (HSC) and quantitation are shown. C57BL/6 mice with established fibrosis
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determine whether the macrophage phenotype was skewed
towards M1 or M2. hAEC treated mice had increased IL-
10 mRNA expression and a significant decrease in the IL-12b:IL-
10 ratio consistent with skewing towards M2 macrophages
(P,0.001 and ,0.05 for single and double doses respectively;
Figure 4C). Macrophages express MMP-9 and MMP-12, which
are important regulators of fibrolysis [27,31]. MMP-9 expression
was elevated while MMP-12 decreased in hAEC treated mice
(P,0.05; Figure 4C).
Discussion
In this study we have shown that intravenously delivered
human AEC engraft in injured livers of immunocompetent mice
and lead to significant changes in hepatic macrophage numbers
and phenotype and significantly reduce the extent of established
induced by prolonged carbon tetrachloride (CCl4) administration were given a single or double hAEC dose. The hAEC-treated mice had significantly
reduced fibrosis area (A) and numbers of activated HSC (B). The concentrations of the main pro-fibrogenic cytokine TGFb-1 in the liver was measured
by ELISA and found to be significantly lower in hAEC-treated mice (C). Murine HSC were treated with hAEC conditioned medium. TGFb-1 and collagen
synthesis declined significantly in HSC exposed to conditioned medium (D). Scale bars =100 mm. *, ** and *** P,0.05, 0.01 and 0.001, respectively.
doi:10.1371/journal.pone.0038631.g002
Figure 3. Human amniotic epithelial cell transplantation lowers hepatic macrophage number and alters monocyte recruitment
factors. Hepatic macrophages were identified by F4/80 immunohistochemistry. C57BL/6 mice with established fibrosis treated with single or double
hAEC doses had significantly lower number of F4/80 positive macrophages in the liver compared with animals given carbon tetrachloride (CCl4) only
(A). The concentrations of monocyte recruitment factors measured by ELISA showed that hAEC treatment led to a significant reduction in MCP-1 and
increased levels of fractalkine in the liver compared to CCl4 treated control animals (B). Scale bar =100 mm. *, ** and *** P,0.05, 0.01 and 0.001,
respectively.
doi:10.1371/journal.pone.0038631.g003
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macrophages. mRNA expression of classically (M1) and alternately activated M2 macrophage genes were analyzed by real time quantitative PCR
and the fold change calculated by the
DDCT method. Expression of M2 associated YM-1, CD206 and IL-10 was significantly elevated in livers of mice
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of intact human IMM protein and HLA-G positive cells up to
four weeks post transplantation. Similar outcomes showing
grafted hAEC remaining several weeks after transplantation
have also been reported in immunocompetent animals with
brain, spinal cord and lung injury [32,33,34,35]. Low levels of
HLA Class IA expression, lack of co-stimulatory molecules
CD80/86 and secreted factors such as TGF-b and IL-6 from
hAEC that can suppress T cell expansion may have limited the
surveillance of the engrafted cells by host T cells [14,16,22,33].
However, anti-human antibodies were generated against the
transplanted hAEC and it would be important to identify the
antigens responsible, immunoglobulin sub-classes and the
survival of hAEC following multiple infusions. Further, chemo-
kines and adhesion molecules that regulate migration of
intravenously infused hAEC to injury sites and subsequent
engraftment remain uncertain.
The importance of our current findings in relation to human
liver disease relates to the use of a model of established hepatic
fibrosis and the evaluation of a second hAEC dose. We
transplanted hAEC into mice only after advanced fibrosis was
established and then continued CCl4 administration following cell
transplantation to simulate the clinical scenario of advanced liver
disease due to persistent liver injury such as that from chronic viral
hepatitis or continued excessive alcohol use. Despite continuing
liver injury from CCl4 exposure, hAEC transplantation resulted in
a significant reduction in hepatic fibrosis area that was accompa-
nied by a decrease in the number of a-SMA positive activated
HSC. The decreased output of TGFb-1, the principal pro-
fibrogenic and regulatory cytokine for HSC activation, in livers of
mice that received hAEC treatment may have led to lower
numbers of collagen-producing HSC. This is supported by our in
vitro finding that hAEC conditioned medium reduced TGFb-1 and
collagen synthesis by murine hepatic stellate cells. Mice receiving
two hAEC infusions showed a marginal increase in the number of
engrafted cells and a small decrease in HSC activation and TGFb-
1 protein levels compared to mice receiving a single infusion.
However in this model, two hAEC infusions did not decrease
fibrosis area to a greater extent than a single infusion. This finding
may relate to the timing of the second hAEC dose with less time
for engraftment (two weeks compared to four weeks after a single
injection). Additionally, the number of cells infused or the route of
cell administration may have been a factor in this outcome.
Overall, these findings extend our previous observations [13] by
demonstrating that hAEC transplantation is effective in reducing
advanced hepatic fibrosis and supports the concept that hAEC
should be further investigated in regard to optimal cell numbers
for multiple transplantations, alternative routes of delivery
(intrahepatic or intrasplenic) to test for maximal cell engraftment
and long term outcomes in this and other animal models of
chronic hepatic fibrosis.
We also investigated the potential role of macrophages in
hepatic fibrosis reduction in this model. Consistent with
previous studies, we found that CCl4-induced liver injury was
associated with a significant increase in hepatic MCP-1,
extensive infiltration of spindle-shaped F4/80 positive macro-
phages into the liver parenchyma and increased fibrosis
compared to untreated controls [19,36]. MCP-1 signalling via
its receptor CCR2 on monocytes has been shown to induce the
trafficking of these cells to sites of injury. Importantly, mice
treated with hAEC had significantly lower levels of hepatic
MCP-1 that correlated with reduced numbers of F4/80 positive
macrophages and reduced fibrosis compared to mice receiving
CCl4 alone. The importance of reduced MCP-1/CCR2
expression on fibrosis has been demonstrated in recent studies
showing that blocking MCP-1 by RNA oligonucleotides
significantly decreases CCl4-induced murine hepatic fibrosis
[37], and that CCR2 knockout mice treated with CCl4 had
significantly reduced hepatic fibrosis [36]. In contrast, we found
that hepatic fractalkine (CX3CL1) protein levels increased
significantly in hAEC treated mice compared to CCl4 alone.
Increases in fractalkine have been shown to reduce HSC
activation and fibrogenesis by inducing IL-10 and Arg-1 in
hepatic macrophages [29]. Further, the interaction of fractalkine
and its receptor, CX3CR1, leads to differentiation of macro-
phages having an anti-inflammatory phenotype (M2) and
prolongs their survival leading to reduced fibrosis [38]. Our
findings showing elevated IL-10 mRNA expression characteristic
of alternately activated macrophages in livers of hAEC treated
mice with increased levels of fractalkine lend support to this
potential mechanism of fibrosis reduction.
The importance of macrophage plasticity in wound healing
and hepatic tissue regeneration is increasingly recognised since
alternatively activated M2 macrophages are thought to contrib-
ute to wound healing by secreting anti-inflammatory cytokines
and collagen degrading enzymes [27,30,39]. Given the changes
in F4/80 positive macrophage numbers and fibrosis with hAEC
treatment, we explored whether the macrophage population
displayed a phenotype consistent with wound healing and tissue
remodelling. M2 macrophages express several distinct genes
including YM-1, Cadm-1, CD206, CD36 and Cnrip-1. Analysis
of hepatic mRNA expression showed that YM-1 mRNA,
a chitinase family member, the anti-inflammatory cytokine IL-
10 and the mannose receptor CD206 produced by alternatively
activated macrophages, were significantly increased in CCl4-
treated mice following hAEC transplantation compared to
control animals given CCl4 alone. A decrease in the ratio of
IL-12b to IL-10 expression further supports skewing towards
a M2 phenotype. In addition, macrophages are an important
source of matrix degrading enzymes. Liver from hAEC treated
mice demonstrated significantly greater expression of MMP-9,
which effectively degrades collagen, and significantly less MMP-
12, which has been reported to inhibit the production of MMP-
9 and increase hepatic fibrosis [40]. These are important new
findings as there are few reports describing the effects of
exogenous stem cells on macrophage phenotype. Mesenchymal
stem cells have very recently been shown to regulate the
switching of macrophages to a M2 phenotype in a murine
model of myocardial infarction [41] and multipotent adult
progenitor cells to induce a beneficial shift from M1 to M2 in
a rat model of spinal cord injury [42]. Recently a therapeutic
avenue using M2 macrophages has been suggested as CCl4-
treated mice infused with alternatively activated macrophages
showed reduced hepatic fibrosis [39]. Therefore, it will be
important to determine the influence of exogenous stem cells on
hepatic macrophages in the setting of liver injury.
In summary, these findings suggest that hAEC induce changes
to macrophage recruitment and promote a wound-healing
treated with hAEC compared to animals given carbon tetrachloride (CCl4) alone (A). M1 associated genes CCL17 and CCL5 were expressed but levels
did not alter with hAEC treatment (B). IL-12b:IL-10 ratio was skewed towards an M2 phenotype. MMP-9 increased and MMP-12 expression decreased
with hAEC treatment (C). *, ** and *** P,0.05, 0.01 and 0.001, respectively.
doi:10.1371/journal.pone.0038631.g004
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Our results offer novel insights into potential mechanisms
underlying the resolution of established hepatic fibrosis induced
by exogenously delivered stem-like cells derived from the human
placenta.
Supporting Information
Figure S1 Cytokeratin staining of human amniotic
epithelial cells. Isolated hAEC show positive staining for
cytokeratin (CK)-7 and CK8/18 by flow cytometry and
immunocytochemistry. Scale bar=100 mm.
(TIF)
Figure S2 The extent of hepatic fibrosis following long
term carbon tetrachloride administration. Sirius red
stained collagen in liver tissue sections obtained from immuno-
competent C57BL/6 mice given twice weekly injections of CCl4
showed increased scarring with bridging fibrosis after 10–12 weeks
(A). Quantitative computer assisted morphometry of Sirius red
stained fibrosis area reflects the significant increase in collagen
deposition with prolonged CCl4 administration (B). Scale bar
=200 mm. * P,0.05.
(TIF)
Figure S3 Human amniotic epithelial cells in liver show
features of hepatocytes. HLA-G positive hAEC stained for
albumin. Some of these cells were also positive for HNF4a.( +VE
= positive, -VE = negative; Scale bar =50 mm).
(TIF)
Figure S4 T cell populations in liver of human amniotic
epithelial cell treated mice. CD3, CD4 and CD8 populations
in liver of hAEC treated and control groups of mice are shown.
Scale bar=50 mm.
(TIF)
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